Table 1 Comparative baseline characteristics of the cohort at JMC, April 10–May 10, 2017
All n = 179 | ABC group (n = 87) | AZT group (n = 92) | P-value | |
|---|---|---|---|---|
Variables | ||||
Sex | Male | 42 (48.3%) | 39 (42.4%) | 0.42 |
Female | 45 (51.7%) | 53 (57.6%) | ||
Age (years) | < 3 years | 11 (12.6%) | 12 (13.0%) | 0.97 |
3–5 years | 18 (20.7%) | 20 (21.7%) | ||
> 5 years | 58 (66.7%) | 60 (65.2%) | ||
BMI (baseline) | <5th centile | 74 (85.0%) | 66 (71.7%) | 0.03 |
>5th centile | 13 (14.9%) | 26 (28.3%) | ||
Maternal HIV status | Positive | 78 (89.7%) | 83 (90.2%) | 0.91 |
Unknown | 9 (10.3%) | 9 (9.8%) | ||
Area of residence | Urban | 66 (75.9%) | 68 (73.9%) | 0.76 |
Rural | 21 (24.1%) | 24 (26.1%) | ||
Baseline CD4+ (Mean + SD) | 166.31 + 76.22 | 178.78 + 71.12 | 0.26 | |
WHO stage | I | 8 (9.2%) | 3 (3.3%) | 0.08 |
II | 24 (27.6%) | 40 (43.5%) | ||
III | 45 (51.7%) | 42 (45.7%) | ||
IV | 10 (11.5%) | 7 (7.6%) | ||
Functional status | W/A | 72 (82.8%) | 88 (95.7%) | 0.001 |
A/D | 12 (13.8%) | 0 (0.0%) | ||
B/R | 3 (3.4%) | 4 (4.3%) | ||
TB (treatment) | Yes | 3 (3.4%) | 9 (9.8%) | 0.06 |
No | 84 (96.6%) | 83 (90.2%) | ||
OI Prophylaxis | Both CPT and INH | 85 (97.7%) | 89 (96.7%) | 0.69 |
CPT only | 1 (1.1%) | 1 (1.1%) | ||
Neither | 1 (1.1%) | 2 (2.2%) | ||
Nutritional status | Normal | 45 (51.7%) | 57 (62.0%) | 0.17 |
SAM | 42 (48.3%) | 35 (38.0%) | ||